Bliss GVS Pharma's board approved the appointment of two new independent directors, Vijayanarayanan Mahadevan and Deepak Rameshchandra Shah, for a five-year term.
The appointments, effective from April 3, 2026, are subject to shareholder approval via a postal ballot, as per the circular resolution passed on April 3, 2026.
The new directors bring extensive experience in finance, taxation, and corporate governance to the board.